Review @natrevneph.nature.com @haanenjohn.bsky.social Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors www.nature.com/articles/s41...

Researchers Veer Keizer and @riklindeboom.bsky.social have both received a Veni grant from the Dutch Research Council to set up and strengthen their own independent research lines ➡️ www.nki.nl/news-events/...

The May issue is live nature.com/nbt/volumes/... On the cover, a ‘green’ platform for template-independent enzymatic synthesis of RNA oligonucleotides using reversible terminator nucleoside triphosphates that offers a sustainable alternative to traditional chemical methods go.nature.com/3zBfDZf

Promising results from Ph 1 trial of autologous PRAME-directed TCR-T cell therapy in HLA-A*02+ patients with PRAME+ recurrent and/or refractory solid tumors. Out now in @naturemedicine.bsky.social! Enrolment for Ph 3 trial of IMA203 ongoing 👇 clinicaltrials.gov/study/NCT067...

In the fight against bacterial pathogens, researchers are combining vaccination with targeted colonisation of the intestine by harmless microorganisms. This approach could potentially mark a turning point in the antibiotics crisis. ethz.ch/en/news-and-...

Check out this insightful animation from @vanrheenenlab.bsky.social @oncodeinstitute.bsky.social visualizing the findings of their recent Nature paper on tumor formation in the breast Paper ➡️ www.nature.com/articles/s41... More on the paper ➡️ www.nki.nl/news-events/... #cancerresearch

New study shows that neoadjuvant durvalumab + chemotherapy could improve outcomes for high-risk upper tract urothelial carcinoma. Explore the latest findings and implications for #oncology practice. ascopost.com/news/april-2... #ASCO2025 #CancerResearch #UrothelialCarcinoma

Neoadjuvant combination immunotherapy may improve treatment response in head and neck cancer. Using two immunotherapy drugs shows better tumor shrinkage and survival benefits compared to single-agent therapy. ascopost.com/news/march-2...

UK 🇬🇧 contingent at #SITCSpringScientific25! What a stimulating meeting - fully dedicated to discussing everything cell therapy for solid tumours. Fantastic faculty & programme + excellent venue! Feeling super inspired! 🌟 Thank you @sitcancer.bsky.social & the organisers! @maxjulve.bsky.social

Excited to be here in San Diego 🇺🇸 for #SITCSpringScientific25 focussing on cellular therapy for solid tumours. 🚀 To kickstart, we hear keynote from @haanenjohn.bsky.social @nkinl.bsky.social sharing experience from academia-led work on TILs - from basic to translational research to clinical trials!

It’s gotten so bad we need a CHART to follow the whiplash firings and re-hirings 🤦🏻‍♂️ Who runs a company like this. Much less a country ??

🌏 Our mission is guided by the C.A.R.E. model, focusing on transforming cancer care in underserved communities globally, implementing accessible care and empowering healthcare professionals. 💪 Learn more: buff.ly/3EtUOkY #cancer #nonprofit #CancerAwareness #oncology #healthcare #globalhealth

New: The largest medical A.I. randomized controlled trial yet performed, enrolling >100,000 women undergoing mammography screening The use of AI led to 29% higher detection of cancer, no increase of false positives, and reduced workload compared with radiologists w/o AI thelancet.com/journals/lan...

Do check out our review on #celltherapy toxicities in solid cancers out now on #ESMO IO tech!

Great to see this out @naturemedicine.bsky.social! Exemplar translational research: autologous T cells (blood), expanded to predicted neoAg (Class I+II). Congratulations @haanenjohn.bsky.social, @sklobuch.bsky.social & team @nkinl.bsky.social for once again advancing #CellTherapy in solid cancers.

Can patterns of progression on IO, inform future decisions? -1377pts from 5 ph 3 trials used to create 3 PD risk levels - low (⬆️existing lesions), intermediate (new lesions), high (both) - risk score assoc w post-PD OS across tumors Prognostic, so far #LCSM jamanetwork.com/journals/jam...

Very proud of my 'partner-in-crime' 🙌 for showcasing our #MANIFESTuk consortium publicly for the first time at #ESMOImmuno24. Go @zaydtippu.bsky.social - you are a star! 🌟 Excited to get going with delivery in 2025! @crick.ac.uk @icrlondon.bsky.social @cruk-mi.bsky.social @mcrcnews.bsky.social

New research shows younger and middle-aged adults have worse long COVID symptoms than older adults "On an average of 10 months after COVID-19 onset, younger (ages 18-44) and middle-aged (ages 45-64) adults had worse neurologic symptoms of long COVID than adults 65 and older." #LongCOVID